Astrazeneca

FromAstraZeneca ([email protected])
Subject (68)Camizestrant reduced the risk of disease progression or death by 56%
Preheader (149)Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour
Typography
Arial
Colors
Text Analysis
Body Words151
Subject Words11
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px760 px
X-Spam Score0.9
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeAfternoon

Camizestrant reduced the risk of disease progression or death by 56%

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumour
Camizestrant reduced the risk of disease progression or death by 56%